SNF472

Sanifit Therapeutics S. A. · Phase 2 active Small molecule

At a glance

Generic name	SNF472
Sponsor	Sanifit Therapeutics S. A.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 3 Study of SNF472 for Calciphylaxis (PHASE3)
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) (PHASE2)
Phase 2 Study With SNF472 in Calciphylaxis Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SNF472 CI brief — competitive landscape report
SNF472 updates RSS · CI watch RSS
Sanifit Therapeutics S. A. portfolio CI